Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Copanlisib - Bayer HealthCare Pharmaceuticals

Drug Profile

Copanlisib - Bayer HealthCare Pharmaceuticals

Alternative Names: Aliqopa; BAY-806946; BAY-841236; Copanlisib hydrochloride

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma; Memorial Sloan-Kettering Cancer Center
  • Developer All Ireland Cooperative Oncology Research Group; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb; Chonnam National University Hospital; H. Lee Moffitt Cancer Center and Research Institute; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Morpholines; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Marginal zone B-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Follicular lymphoma
  • Phase III Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase II Cholangiocarcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Mantle-cell lymphoma
  • Phase I/II Breast cancer; Colorectal cancer; Peripheral T-cell lymphoma; Solid tumours
  • Phase I Lymphoma; Urogenital cancer

Most Recent Events

  • 06 Dec 2019 Updated efficacy and adverse events data from the phase II CHRONOS-1 trial in Non-Hodgkin's lymphoma released by Bayer
  • 21 Nov 2019 Pooled safety data from Phase II CHRONOS-1 and 8 phase I trials in Haematologic malignancies released by Bayer HealthCare Pharmaceuticals
  • 13 Aug 2019 Bayer completes a phase I trial in Solid tumours and Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in USA and Canada (NCT02253420)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top